Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …

Simple Summary The development of CAR-T cell clinical trials has accelerated over the last
two decades. These trials, collected on Clinicaltrial. gov until 2022, come mainly from the …

Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …

Genome editing of allogeneic T cells can provide “off-the-shelf” alternatives to autologous
chimeric antigen receptor (CAR) T cell therapies. Disruption of T cell receptor α chain …

Background Chimeric antigen receptor (CAR) T-cell therapy is a promising option for
patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the …

Chimeric antigen receptor (CAR) T cells are changing the therapeutic landscape for
hematological malignancies. To date, all six CAR T cell products approved by the US Food …

Tumor immunotherapy, particularly the use of immune checkpoint inhibitors, has yielded
impressive clinical benefits. Therefore, it is critical to accurately screen individuals for …

Persistence or recurrence of large B-cell lymphoma after CD19-CAR-T is common, yet data
guiding management are limited. We describe outcomes and features following CAR-T …

Abstract Chimeric Antigen Receptor (CAR) T cell therapy is an effective treatment approach
for patients with relapsed or refractory acute lymphoblastic leukemia (R/R B-ALL). However …

In October 2021, brexucabtagene autoleucel became the first anti-CD19 chimeric antigen
receptor T-cell product to receive approval from the Food and Drug Administration to treat …